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S U M M A R Y
Background: As part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) we report antimicrobial
resistance among Gram-positive and Gram-negative isolates collected globally from integumentary
sources between 2010 and 2014.
Methods: Minimum inhibitory concentrations and antimicrobial resistance were determined according
to Clinical and Laboratory Standards Institute guidelines (US Food and Drug Administration breakpoints
against tigecycline). The Cochran–Armitage trend test was used to identify statistically signiﬁcant
changes in resistance.
Results: Global rates of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant
Acinetobacter baumannii were 38% and 43%, respectively. No S. aureus isolates were resistant to linezolid
or vancomycin; all isolates were susceptible to tigecycline. Two percent of Enterococcus faecalis and 28%
of Enterococcus faecium were vancomycin-resistant. Extended-spectrum b-lactamase (ESBL) producers
accounted for 22% of Klebsiella pneumoniae and 16% of Escherichia coli. Resistance to minocycline among
E. faecalis, E. faecium, K. pneumoniae, and E. coli decreased signiﬁcantly (p < 0.0001). There were
signiﬁcant increases (p < 0.0001) in A. baumannii resistance to cefepime, ceftazidime, ceftriaxone,
levoﬂoxacin, meropenem, and piperacillin–tazobactam.
Conclusions: Among isolates from integumentary sources, rates of MRSA and ESBL-producing
Enterobacteriaceae are stabilizing. Carbapenems and tigecycline have retained their in vitro activity
against Gram-positive and Gram-negative organisms. Few agents were active against A. baumannii; its
increasing resistance is cause for concern.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Skin and skin structure infections (SSSIs) are mostly uncompli-
cated (for example, impetigo and furuncles) and involve invasion of
the dermis or epidermis by Gram-positive bacteria, most frequently
Staphylococcus aureus and Streptococcus pyogenes.1–3 Complicated
SSSIs (cSSSIs) arise when bacterial infection involves deeper soft
tissues (for example, fascia and muscle), and surgical intervention
is often required.3 These cSSSIs include secondary skin infections* Corresponding author. Tel.: +46 10 103 2097.
E-mail address: maria.tarnberg@liu.se (M. Ta¨rnberg).
http://dx.doi.org/10.1016/j.ijid.2016.06.016
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).that arise from pre-existing nosocomial infections, predisposing risk
factors, or comorbidities such as chronic skin conditions, vascular
insufﬁciency, peripheral neuropathy, immunodeﬁciency, diabetes
mellitus, cellulitis, or obesity.2,4 Causative pathogens associated
with cSSSIs include Gram-positive and Gram-negative organisms, as
well as their resistant phenotypes, such as methicillin-resistant S.
aureus (MRSA).5,6 Gram-negative organisms associated with cSSSIs
include Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, and
Pseudomonas aeruginosa.7 Complicated SSSIs pose diagnostic and
therapeutic challenges and usually require intravenous antibiotic
therapy, surgical intervention, and hospitalization, which contribute
to increasing morbidity and mortality rates, as well as being an
economic and healthcare burden.5,8,9ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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activity against Gram-positive and Gram-negative organisms, as
well as multidrug-resistant (MDR) pathogens. It is licensed for the
treatment of cSSSIs, complicated intra-abdominal infections
(cIAIs), and community-acquired bacterial pneumonia in the
USA, and for cSSSIs and cIAIs in Europe.10,11
The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a
global multicentre antimicrobial surveillance study that com-
menced in 2004. The study monitors the in vitro activity of
tigecycline and comparator agents against a range of clinically
important Gram-positive and Gram-negative organisms. This
paper reports the antimicrobial resistance rates among isolates
collected globally from integumentary sources between 2010 and
2014, and serves as an update of the previous publication by
Namdari et al., which covered the period 2004–2009.12 Also
presented is an analysis of rates of antimicrobial resistance among
isolates collected between 2004 and 2014.
2. Materials and methods
Between 2010 and 2014, global centres participating in T.E.S.T.
submitted a minimum of 65 Gram-positive and 135 Gram-
negative isolates. A range of culture sources were acceptable,
including integumentary sources such as abscesses, burns,
cellulitis, skin ulcers, and wounds. Isolates from both inpatients
and outpatients with documented hospital- or community-
acquired infections were included in the study. Only a single
isolate per patient was allowed in the study, and patient age, sex,
medical history, and previous antimicrobial use were not
considered relevant. International Health Management Associates
(IMHA, Schaumburg, IL, USA) were responsible for isolate
collection, identiﬁcation, and transportation, and for management
of a centralized database. Quality control checks were carried out
on approximately 10% of isolates annually.
Broth microdilution methodology according to the Clinical
and Laboratory Standards Institute (CLSI) guidelines13 was used
to determine minimum inhibitory concentrations (MICs);
detailed methodology has been described elsewhere.14 The
antimicrobial panel included amoxicillin–clavulanate, ampicil-
lin, ceftriaxone, levoﬂoxacin, meropenem, minocycline, piper-
acillin–tazobactam, and tigecycline. In addition, Gram-negative
organisms were tested against amikacin, cefepime, and cefta-
zidime, and Gram-positive organisms were tested against
linezolid, penicillin, and vancomycin. Antimicrobial susceptibil-
ity was determined using CLSI interpretive criteria,15 except for
tigecycline for which the US Food and Drugs Administration-
approved breakpoints were used.16Table 1
Global rates of resistant phenotypes of Gram-positive and Gram-negative organisms colle
data, 2010–2014 and 2004–2014)
Staphylococcus aureus Enterococcus
faecalis
Enterococcus
faecium
Klebs
pneu
MRSA Vancomycin-
resistant
Vancomycin-
resistant
ESBL
n/N % n/N % n/N % n/N 
2010 416/1151 36.1 5/279 1.8 16/83 19.3 96/3
2011 345/872 39.6 3/246 1.2 28/78 35.9 35/2
2012 512/1268 40.4 6/231 2.6 27/94 28.7 60/2
2013 379/1127 33.6 4/291 1.4 21/88 23.9 77/3
2014 274/700 39.1 4/170 2.4 23/74 31.1 33/1
2010–2014 1926/5118 37.6a 22/1217 1.8a 115/417 27.6a 301/
2004–2014 5065/12 363 41.0b 75/3151 2.4a 332/945 35.1b 674/
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MRSA, methicillin-resistant Stap
a Indicates non-signiﬁcant change in resistance; a cut-off of p < 0.01 was used for st
b Indicates a signiﬁcant decrease in resistance; a cut-off of p < 0.01 was used for sta
c Indicates a signiﬁcant increase in resistance; a cut-off of p < 0.01 was used for statMethicillin resistance in S. aureus and extended-spectrum b-
lactamase (ESBL) production among E. coli and Klebsiella spp. was
determined by IHMA according to CLSI guidelines.15
Multidrug resistance in this study was deﬁned as resistance to
three or more classes of antimicrobial agents. The classes used to
deﬁne MDR Acinetobacter baumannii were aminoglycosides
(amikacin), b-lactams (cefepime, ceftazidime, ceftriaxone, or
piperacillin–tazobactam), carbapenems (imipenem/meropenem),
ﬂuoroquinolones (levoﬂoxacin), and tetracyclines (minocycline);
the classes used to deﬁne MDR P. aeruginosa were aminoglycosides
(amikacin), b-lactams (cefepime, ceftazidime, or piperacillin–
tazobactam), carbapenems (imipenem/meropenem), and ﬂuoro-
quinolones (levoﬂoxacin).
Statistically signiﬁcant changes in resistance between 2010–
2014 and 2004–2014 were analyzed using the Cochran–Armitage
trend test. Due to the large volume of trend tests undertaken, p-
values of p < 0.01 were regarded as statistically signiﬁcant.
3. Results
Data are presented for a total of 13 856 isolates: 6752 Gram-
positive and 7104 Gram-negative strains collected from integu-
mentary sources between 2010 and 2014. In total, 274 global
T.E.S.T. study centres submitted isolates between 2010 and 2014:
six centres in Africa, 153 in Europe, 31 in Latin America, 11 in the
Middle East, and 73 centres in North America. The Asia-Paciﬁc Rim
did not submit isolates between 2010 and 2014. Not every centre
submitted isolates every year.
3.1. Gram-positive organisms
3.1.1. Staphylococcus aureus
Between 2010 and 2014, a total of 5118 isolates of S. aureus
sourced globally from integumentary sources were submitted to
T.E.S.T., of which 38% were MRSA (Table 1). MRSA rates varied from
26%–30% in Africa, Europe, and the Middle East, to 50% in North
America and 55% in Latin America (Table 2).
Among S. aureus, global rates of resistance were highest to
levoﬂoxacin (32%); 70% of MRSA isolates were resistant to
levoﬂoxacin. No S. aureus isolates were resistant to linezolid or
vancomycin; all isolates were susceptible to tigecycline (Table 3).
Overall, global rates of MRSA signiﬁcantly decreased between
2004 and 2014 (p < 0.0001) (Table 1). Resistance among MRSA to
levoﬂoxacin, linezolid, tigecycline, and vancomycin for the period
2004–2014 were comparable to resistance rates reported between
2010 and 2014 (Table 3).cted from integumentary sources as part of T.E.S.T. between 2010 and 2014 (pooled
iella
moniae
Escherichia coli Acinetobacter
baumannii
Pseudomonas
aeruginosa
-producing ESBL-producing Multidrug-
resistant
Multidrug-
resistant
% n/N % n/N % n/N %
40 28.2 75/459 16.3 163/385 42.3 86/584 14.7
16 16.2 69/384 18.0 88/305 28.9 30/461 6.5
90 20.7 67/380 17.6 109/210 51.9 41/516 7.9
13 24.6 76/471 16.1 115/231 49.8 51/612 8.3
84 17.9 40/297 13.5 58/104 55.8 20/362 5.5
1343 22.4a 327/1991 16.4a 533/1235 43.2c 228/2535 9.0b
3173 21.2a 623/4537 13.7c 1190/3429 34.7c 580/6038 9.6a
hylococcus aureus; ESBL, extended-spectrum b-lactamase.
atistical signiﬁcance testing.
tistical signiﬁcance testing.
istical signiﬁcance testing.
Table 2
Regional rates of resistant phenotypes of Gram-positive and Gram-negative organisms from integumentary sources as part of T.E.S.T. between 2010 and 2014 (pooled data,
2010–2014 and 2004–2014)a
2010 2011 2012 2013 2014 2010–2014 2004–2014
n/N % n/N % n/N % n/N % n/N % n/N % n/N %
Staphylococcus aureus: MRSA
Africa 0/0 - 9/28 32.1 12/42 28.6 4/28 14.3 0/0 - 25/98 25.5 68/210 32.4
Europe 174/619 28.1 118/467 25.3 248/690 35.9 165/633 26.1 127/423 30.0 832/2832 29.4 1481/5231 28.3
Latin America 53/94 56.4 15/22 68.2 15/32 46.9 11/26 42.3 20/34 58.8 114/208 54.8 338/685 49.3
Middle East 11/52 21.2 7/12 58.3 14/43 32.6 8/26 30.8 0/0 - 40/133 30.1 85/334 25.4
North America 161/322 50.0 196/343 57.1 223/461 48.4 191/414 46.1 127/243 52.3 898/1783 50.4 2910/5437 53.5
Enterococcus faecalis: vancomycin-resistant
Africa 0/0 - 0/9 - 0/16 0.0 0/8 - 0/0 - 0/33 0.0 0/54 0.0
Europe 1/149 0.7 1/132 0.8 2/106 1.9 2/153 1.3 1/98 1.0 7/638 1.1 10/1228 0.8
Latin America 0/25 0.0 0/4 - 0/8 - 0/12 0.0 0/10 0.0 0/59 0.0 0/251 0.0
Middle East 0/9 - 0/1 - 0/9 - 0/8 - 0/0 - 0/27 0.0 0/79 0.0
North America 4/92 4.3 2/100 2.0 4/92 4.3 2/110 1.8 3/62 4.8 15/456 3.3 64/1453 4.4
Enterococcus faecium: vancomycin-resistant
Africa 0/0 - 0/0 - 0/1 - 0/3 - 0/0 - 0/4 - 0/10 0.0
Europe 1/48 2.1 7/50 14.0 2/57 3.5 6/64 9.4 10/58 17.2 26/277 9.4 46/462 10.0
Latin America 1/5 - 0/0 - 0/1 - 0/0 - 1/2 - 2/8 - 13/63 20.6
Middle East 1/4 - 0/0 - 3/4 - 0/2 - 0/0 - 4/10 40.0 7/18 38.9
North America 13/21 61.9 21/28 75.0 22/31 71.0 15/19 78.9 12/14 85.7 83/113 73.5 261/365 71.5
Klebsiella pneumoniae: ESBL-producing
Africa 0/0 - 3/7 - 10/19 52.6 6/12 50.0 0/0 - 19/38 50.0 37/85 43.5
Europe 60/187 32.1 20/111 18.0 24/144 16.7 43/178 24.2 26/119 21.8 173/739 23.4 306/1344 22.8
Latin America 16/39 41.0 0/5 - 3/5 - 6/11 54.5 4/10 40.0 29/70 41.4 128/306 41.8
Middle East 11/31 35.5 5/6 - 8/21 38.1 11/20 55.0 0/0 - 35/78 44.9 54/147 36.7
North America 1/69 1.4 7/87 8.0 15/101 14.9 11/92 12.0 3/55 5.5 37/404 9.2 121/1196 10.1
Escherichia coli: ESBL-producing
Africa 0/0 - 3/11 27.3 5/16 31.3 4/20 20.0 0/0 - 12/47 25.5 15/87 17.2
Europe 40/261 15.3 50/217 23.0 37/203 18.2 47/269 17.5 29/205 14.1 203/1155 17.6 344/2059 16.7
Latin America 20/65 30.8 11/23 47.8 3/10 30.0 4/18 22.2 6/17 35.3 44/133 33.1 121/411 29.4
Middle East 7/30 23.3 2/11 18.2 12/32 37.5 7/24 29.2 0/0 - 28/97 28.9 43/183 23.5
North America 5/92 5.4 3/122 2.5 10/119 8.4 14/140 10.0 5/75 6.7 37/548 6.8 75/1689 4.4
Acinetobacter baumannii: MDR
Africa 0/0 - 4/10 40.0 3/5 - 7/10 70.0 0/0 - 14/25 56.0 32/58 55.2
Europe 89/210 42.4 50/176 28.4 64/108 59.3 63/126 50.0 32/55 58.2 298/675 44.1 516/1499 34.4
Latin America 23/39 59.0 0/0 - 5/6 - 4/8 - 6/7 - 38/60 63.3 125/203 61.6
Middle East 12/23 52.2 8/13 61.5 11/17 64.7 7/8 - 0/0 - 38/61 62.3 75/115 65.2
North America 26/94 27.7 26/106 24.5 26/74 35.1 34/79 43.0 20/42 47.6 132/395 33.4 378/1404 26.9
Pseudomonas aeruginosa: MDR
Africa 0/0 - 5/12 41.7 2/20 10.0 4/18 22.2 0/0 - 11/50 22.0 16/144 11.1
Europe 53/339 15.6 18/304 5.9 21/285 7.4 26/375 6.9 12/222 5.4 130/1525 8.5 256/2750 9.3
Latin America 21/63 33.3 4/9 - 6/16 37.5 3/14 21.4 2/14 14.3 36/116 31.0 122/430 28.4
Middle East 3/23 13.0 1/14 7.1 5/33 15.2 10/30 33.3 0/0 - 19/100 19.0 33/209 15.8
North America 5/134 3.7 2/122 1.6 7/162 4.3 8/175 4.6 6/126 4.8 28/719 3.9 110/2264 4.9
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended-spectrum b-lactamase; MDR, multidrug-resistant.
a Data for the Asia-Paciﬁc region are not presented as centres in this region stopped participation in T.E.S.T. in 2010. ‘-’ % resistance not calculated when N < 10 isolates.
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Of the 1217 E. faecalis isolates submitted globally between
2010 and 2014, 2% were vancomycin-resistant (Table 1). No
vancomycin-resistant isolates were collected from Africa, Latin
America, or the Middle East; seven vancomycin-resistant isolates
were collected from Europe and 15 isolates from North America
(Table 2).
Among E. faecalis, global resistance was highest to levoﬂoxacin
(31%). Resistance to minocycline was highest in 2010 (50%),
decreased by 38% in 2011, and then remained below 9% for the
subsequent years of collection (p < 0.0001). Between 2010 and
2014 resistance to ampicillin and penicillin was low (1%). Among E.
faecalis, 99.8% of isolates were susceptible to tigecycline. No
resistance to linezolid was seen among E. faecalis isolates (Table 3).
3.1.3. Enterococcus faecium
Of the 417 E. faecium isolates collected globally (2010–2014),
28% were vancomycin-resistant (Table 1). Between 2010 and
2014 global resistance to vancomycin ﬂuctuated between 19%
and 36% (Table 3). The highest rates of vancomycin resistance
were seen in North America (74%). In Europe, 9% of isolates were
vancomycin-resistant. Fewer than ﬁve resistant isolates weresubmitted from Africa, Latin America, and the Middle East
between 2010 and 2014 (Table 2).
High percentages (>80%) of E. faecium isolates were resistant to
ampicillin, penicillin, and levoﬂoxacin. Among E. faecium, global
resistance to minocycline was highest in 2010 (22%), and
decreased to 4% in 2014 (p < 0.0001). A single E. faecium isolate
submitted from Europe in 2010 showed resistance to linezolid; no
other isolates were linezolid-resistant. All E. faecium isolates were
susceptible to tigecycline (Table 3).
Between 2004 and 2014 there was a signiﬁcant decrease in the
global rate of vancomycin-resistant E. faecium (p < 0.0001)
(Table 1). The MICs of three E. faecium isolates submitted between
2004 and 2014 were above the susceptibility breakpoint for
tigecycline (Table 3).
3.2. Gram-negative organisms
3.2.1. Klebsiella pneumoniae
Of the 1343 K. pneumoniae isolates collected globally between
2010 and 2014, 22% were ESBL-producers (Table 1). Rates of ESBL
production ranged from 9% in North America to 50% in Africa
(Table 2).
Table 3
Global MIC90 values (mg/L) and in vitro resistance rates of Gram-positive organisms collected from integumentary sources as part of T.E.S.T. between 2010 and 2014 (pooled
data, 2010–2014 and 2004–2014)
2010 2011 2012 2013 2014 2010–2014 2004–2014
MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R p-Value MIC90 % R p-Value
S. aureusa,b N = 1151 N = 872 N = 1268 N = 1127 N = 700 N = 5118 N = 12 363
Levoﬂoxacin 16 29.9 32 34.3 16 33.4 16 28.9 16 33.4 16 31.8 NS 16 32.3 NS
Linezolid 4 0.0 2 0.0 2 0.0 2 0.0 2 0.0 2 0.0 - 2 0.0 -
Minocycline 1 1.8 0.5 0.2 0.25 0.0 0.25 0.0 0.25 0.0 0.5 0.4 < 0.0001d 0.5 0.6 NS
Tigecyclinec 0.25 (0) 0.25 (0) 0.12 (0) 0.12 (0) 0.12 (0) 0.25 (0) - 0.25 (0) -
Vancomycin 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0 - 1 0.0 -
MRSAa N = 416 N = 345 N = 512 N = 379 N = 274 N = 1926 N = 5065
Levoﬂoxacin 32 69.7 32 70.7 32 68.6 32 70.2 32 69.3 32 69.6 NS 32 68.1 <0.01
Linezolid 2 0.0 2 0.0 2 0.0 2 0.0 2 0.0 2 0.0 - 2 0.0 -
Minocycline 4 2.6 0.5 0.3 0.25 0.0 0.5 0.0 0.25 0.0 0.5 0.6 <0.0001d 0.5 0.9 NS
Tigecyclinec 0.25 (0) 0.25 (0) 0.12 (0) 0.25 (0) 0.25 (0) 0.25 (0) - 0.25 (0) -
Vancomycin 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0 - 1 0.0 -
E. faecalis N = 279 N = 246 N = 231 N = 291 N = 170 N = 1217 N = 3151
Amox/clav 1 - 1 - 0.5 - 1 - 1 - 1 - - 1 - -
Ampicillin 2 0.4 1 1.6 1 1.7 1 1.0 1 0.0 2 1.0 NS 2 0.4 <0.01
Ceftriaxone 128 - 128 - 128 - 128 - 128 - 128 - - 128 - -
Levoﬂoxacin 64 33.3 64 30.1 64 34.2 64 30.6 64 25.9 64 31.1 NS 64 33.1 <0.01d
Linezolid 2 0.0 2 0.0 2 0.0 2 0.0 2 0.0 2 0.0 - 2 0.1 NS
Meropenem 8 - 8 - 8 - 8 - 8 - 8 - - 8 - -
Minocycline 16 49.5 16 11.4 8 7.4 8 6.2 8 8.8 16 17.7 <0.0001d 16 22.9 NS
Penicillin 4 0.4 4 2.4 4 1.7 4 1.0 4 0.0 4 1.2 NS 4 0.6 <0.01
Pip/taz 8 - 4 - 4 - 4 - 4 - 4 - - 4 - -
Tigecyclinec 0.25 (0) 0.12 (1) 0.12 (0) 0.12 (0) 0.12 (1) 0.25 (2) - 0.25 (9) -
Vancomycin 2 1.8 2 1.2 2 2.6 2 1.4 2 2.4 2 1.8 NS 2 2.4 NS
E. faecium N = 83 N = 78 N = 94 N = 88 N = 74 N = 417 N = 945
Amox/clav 16 - 16 - 16 - 16 - 16 - 16 - - 16 - -
Ampicillin 32 85.5 32 84.6 32 77.7 32 89.8 32 85.1 32 84.4 NS 32 81.7 NS
Ceftriaxone 128 - 128 - 128 - 128 - 128 - 128 - - 128 - -
Levoﬂoxacin 64 84.3 64 85.9 64 75.5 64 88.6 64 86.5 64 83.9 NS 64 82.4 NS
Linezolid 2 1.2 2 0.0 2 0.0 2 0.0 2 0.0 2 0.2 NS 2 0.3 NS
Meropenem 32 - 32 - 32 - 32 - 32 - 32 - - 32 - -
Minocycline 16 21.7 16 11.5 8 9.6 8 4.5 8 4.1 16 10.3 <0.0001d 16 13.0 NS
Penicillin 16 85.5 16 82.1 16 76.6 16 85.2 16 79.7 16 81.8 NS 16 81.3 NS
Pip/taz 32 - 32 - 32 - 32 - 32 - 32 - - 32 - -
Tigecyclinec 0.25 (0) 0.12 (0) 0.12 (0) 0.12 (0) 0.12 (0) 0.12 (0) - 0.12 (3) -
Vancomycin 64 19.3 64 35.9 64 28.7 64 23.9 64 31.1 64 27.6 NS 64 35.1 <0.0001d
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MIC90, minimum inhibitory concentration required to inhibit growth of 90% of isolates (mg/l); R, resistance; S. aureus,
Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; Amox/clav, amoxicillin–
clavulanate; Pip/taz, piperacillin–tazobactam; NS, not signiﬁcant; ‘-’, no CLSI breakpoints available.
a Amoxicillin–clavulanate, ampicillin, ceftriaxone, meropenem, penicillin, and piperacillin–tazobactam are not active against S. aureus, therefore their data are not
presented.
b S. aureus data include MRSA data.
c No resistance breakpoint is available, number of isolates above the susceptibility breakpoint given in parentheses.
d Indicates a signiﬁcant decrease in resistance; otherwise a signiﬁcant result indicates an increase in resistance. A cut-off of p < 0.01 was used for statistical signiﬁcance
testing.
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resistant to ceftriaxone, 25% were resistant to cefepime, and 23% of
isolates were resistant to each of amoxicillin–clavulanate and
levoﬂoxacin. Resistance to piperacillin–tazobactam and merope-
nem was 17% and 8%, respectively. Resistance to minocycline in
2010 was 32%, decreased by 21% in 2011, and then remained below
16% (p < 0.0001). Less than 2% of K. pneumoniae isolates were
resistant to amikacin and tigecycline (Table 4).
Pooled data for the 2004–2014 time period show signiﬁcant
increases in rates of resistance among K. pneumoniae isolates to
cefepime and ceftriaxone (p < 0.0001), levoﬂoxacin (p < 0.001),
and amoxicillin–clavulanate, meropenem, piperacillin–tazobac-
tam, and tigecycline (p < 0.01) (Table 4).
3.2.2. Escherichia coli
Of the 1991 E. coli isolates submitted globally between
2010 and 2014, 16% were ESBL-producers (Table 1). Rates of
ESBL-producing isolates varied between regions, with the highest
rate recorded for Latin America (33%) (Table 2).
Among all E. coli isolates, the highest level of resistance was
observed for ampicillin (66%) (Table 4). Thirty-four percent ofisolates were resistant to levoﬂoxacin and 22% were resistant to
ceftriaxone. There were moderate levels of resistance to amoxicil-
lin–clavulanate (15%) and cefepime (13%). Resistance to minocy-
cline decreased from 19% in 2010 to 9% in 2011 and thereafter
remained below 8% (p < 0.0001). Overall resistance to piperacillin–
tazobactam was low (6%). Less than 1% of E. coli isolates were
resistant to amikacin and meropenem, with no isolates resistant to
tigecycline (Table 4).
Pooled data for the period 2004–2014 showed a signiﬁcant
increase in rates of ESBL-producing E. coli (p < 0.0001) (Table 1).
During this period there were signiﬁcant increases in resistance
among E. coli isolates to cefepime and ceftriaxone (p < 0.0001),
ampicillin and levoﬂoxacin (p < 0.01) (Table 4).
3.2.3. Acinetobacter baumannii
Overall, 1235 isolates of A. baumannii were submitted globally
between 2010 and 2014. Forty-three percent of these were MDR
strains, with resistance rates increasing from 29% in 2011 to 56% in
2014. There was a signiﬁcant increase in rates of MDR A. baumannii
between 2010 and 2014 (Table 1). By region, Latin America and the
Middle East had the highest levels of multidrug resistance (63% and
Table 4
Global MIC90 values (mg/L) and in vitro resistance of Gram-negative Enterobacteriaceae organisms collected from integumentary sources as part of T.E.S.T. between 2010 and
2014 (pooled data, 2010–2014 and 2004–2014)
2010 2011 2012 2013 2014 2010–2014 2004–2014
MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R p-Value MIC90 % R p-Value
K. pneumoniae N = 340 N = 216 N = 290 N = 313 N = 184 N = 1343 N = 3173
Amikacin 16 1.2 4 1.4 16 2.1 16 2.6 4 0.0 16 1.6 NS 16 2.9 NS
Amox/clav 64 29.4 32 1.5 64 23.1 64 22.7 64 21.7 64 22.7 NS 64 21.1 <0.01
Cefepime 64 27.4 64 16.7 64 26.9 64 29.1 64 19.0 64 24.8 NS 64 20.3 <0.0001
Ceftriaxone 128 40.3 64 23.6 64 31.7 64 37.1 64 28.8 64 33.4 NS 128 30.5 <0.0001
Levoﬂoxacin 16 30.0 16 15.3 16 20.7 16 25.6 16 18.5 16 23.0 NS 16 21.1 <0.001
Meropenem 0.5 6.2 0.12 4.6 4 10.7 4 10.2 0.25 6.5 1 7.9 NS 0.5 6.7 <0.01
Minocycline 32 31.8 16 11.1 16 12.4 16 15.7 16 14.7 16 18.2 <0.0001a 16 17.1 NS
Pip/taz 256 19.4 32 8.8 256 18.3 256 18.5 256 14.7 256 16.6 NS 256 15.4 <0.01
Tigecycline 2 0.9 1 0.5 2 2.4 2 1.3 2 0.5 2 1.2 NS 2 0.7 <0.01
E. coli N = 459 N = 384 N = 380 N = 471 N = 297 N = 1991 N = 4537
Amikacin 8 0.4 8 0.0 8 0.3 8 0.6 8 0.0 8 0.3 NS 8 0.8 NS
Amox/clav 32 18.1 32 16.7 32 14.7 32 10.2 32 18.9 32 15.4 NS 32 16.1 NS
Ampicillin 64 68.8 64 65.4 64 63.9 64 63.1 64 69.7 64 66.0 NS 64 64.7 <0.01
Cefepime 32 13.5 32 14.1 32 13.7 16 13.2 16 11.1 32 13.2 NS 16 11.3 <0.0001
Ceftriaxone 128 25.7 64 22.4 64 23.2 64 19.5 64 20.5 64 22.4 NS 64 20.0 <0.0001
Levoﬂoxacin 16 35.7 16 35.7 16 31.6 16 31.6 16 35.7 16 34.0 NS 16 33.1 <0.01
Meropenem 0.06 0.2 0.06 0.0 0.12 0.5 0.06 0.8 0.06 0.0 0.06 0.4 NS 0.06 0.5 NS
Minocycline 16 19.0 8 9.4 8 7.6 8 6.4 8 7.1 16 10.2 <0.0001a 16 12.0 NS
Pip/taz 32 6.5 32 8.1 16 4.5 16 3.6 16 5.1 16 5.5 NS 16 4.7 NS
Tigecycline 0.5 0.0 0.25 0.0 0.25 0.0 0.5 0.0 0.25 0.0 0.5 0.0 - 0.5 0.0 -
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MIC90, minimum inhibitory concentration required to inhibit growth of 90% of isolates (mg/l); R, resistance; Amox/clav,
amoxicillin–clavulanate; Pip/taz, piperacillin–tazobactam; K. pneumoniae, Klebsiella pneumoniae; E. coli, Escherichia coli; NS, not signiﬁcant; ‘-’, no CLSI breakpoints available.
a Indicates a signiﬁcant decrease in resistance; otherwise a signiﬁcant result indicates an increase in resistance. A cut-off of p < 0.01 was used for statistical signiﬁcance
testing.
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(Table 2).
Between 2010 and 2014, statistically signiﬁcant increases in
global resistance were seen among A. baumannii isolates to
cefepime, ceftazidime, ceftriaxone, levoﬂoxacin, meropenem,
and piperacillin–tazobactam (p < 0.0001) (Table 5). By 2014,
resistance to these antimicrobials ranged from 57% to 63%.Table 5
Global MIC90 values (mg/L) and in vitro resistance of Gram-negative non-Enterobacteri
2010 and 2014 (pooled data, 2010–2014 and 2004–2014)
2010 2011 2012 2013 
MIC90 % R MIC90 % R MIC90 % R MIC90 % R 
A. baumannii N = 385 N = 305 N = 210 N = 231 
Amikacin 128 33.8 128 21.6 128 35.2 128 31.2
Amox/clav 64 - 64 - 64 - 64 - 
Ampicillin 64 - 64 - 64 - 64 - 
Cefepime 64 34.5 64 30.5 64 51.0 64 55.4
Ceftazidime 64 45.2 32 32.8 32 51.9 32 62.3
Ceftriaxone 128 50.6 64 33.4 64 53.8 64 64.5
Levoﬂoxacin 16 44.2 16 29.5 16 51.0 16 54.5
Meropenem 32 41.3 32 32.1 32 54.3 32 52.4
Minocycline 8 8.8 8 3.3 8 4.8 16 10.8
Pip/taz 256 48.6 256 34.8 256 54.3 256 58.9
Tigecycline 2 - 1 - 1 - 2 - 
P. aeruginosa N = 584 N = 461 N = 516 N = 612 
Amikacin 32 6.2 8 2.2 16 3.1 8 3.8 
Amox/clav 64 - 64 - 64 - 64 - 
Ampicillin 64 - 64 - 64 - 64 - 
Cefepime 32 13.5 16 8.9 16 7.6 32 10.5
Ceftazidime 32 23.5 16 9.5 16 9.5 32 11.8
Ceftriaxone 128 - 64 - 64 - 64 - 
Levoﬂoxacin 16 30.8 16 22.6 16 24.4 16 24.2
Meropenem 16 20.9 16 17.4 16 20.9 16 16.3
Minocycline 32 - 32 - 32 - 32 - 
Pip/taz 256 21.4 64 8.2 64 7.6 128 10.6
Tigecycline 16 - 16 - 16 - 16 - 
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MIC90, minimum inhibitory con
baumannii, Acinetobacter baumannii; P. aeruginosa, Pseudomonas aeruginosa; Amox/clav, a
CLSI breakpoints available.
a Indicates a signiﬁcant decrease in resistance; otherwise a signiﬁcant result indicate
testing.Between 2010 and 2014 the greatest increases in resistance
among A. baumannii isolates were seen for cefepime and
meropenem, rising from 35% to 59%, and 41% to 63%, respectively.
There was a greater than 10% increase in resistance to ceftazidime
(45% in 2010 to 57% in 2014), levoﬂoxacin (44% to 58%), and
piperacillin–tazobactam (49% to 60%). Resistance to ceftriaxone
increased by 9% from 2010 to 2014. Thirty-one percent of isolatesaceae organisms collected from integumentary sources as part of T.E.S.T. between
2014 2010–2014 2004–2014
MIC90 % R MIC90 % R p-Value MIC90 % R p-Value
N = 104 N = 1235 N = 3429
 128 37.5 128 30.9 NS 128 25.6 <0.0001
64 - 64 - - 64 - -
64 - 64 - - 64 - -
 64 58.7 64 42.3 <0.0001 64 36.0 <0.0001
 32 56.7 32 47.4 <0.0001 64 43.7 <0.0001
 64 59.6 64 50.3 <0.0001 128 47.0 <0.0001
 16 57.7 16 44.8 <0.0001 16 40.4 <0.0001
 32 62.5 32 45.1 <0.0001 32 39.1 <0.0001
 8 2.9 8 6.6 NS 8 4.7 <0.0001
 256 59.6 256 49.0 <0.0001 256 40.1 <0.0001
2 - 2 - - 2 - -
N = 362 N = 2535 N = 6038
8 3.3 16 3.8 NS 16 4.6 NS
64 - 64 - - 64 - -
64 - 64 - - 64 - -
 16 6.4 16 9.7 <0.01a 32 10.4 NS
 16 8.0 32 13.1 <0.0001a 32 14.5 NS
64 - 64 - - 128 - -
 16 20.7 16 25.0 <0.01a 16 27.0 <0.01a
 16 14.9 16 18.3 NS 16 18.0 NS
32 - 32 - - 32 - -
 32 5.5 128 11.3 <0.0001a 128 12.3 NS
16 - 16 - - 16 - -
centration required to inhibit growth of 90% of isolates (mg/l); R, resistance; A.
moxicillin–clavulanate; Pip/taz, piperacillin–tazobactam; NS, not signiﬁcant; ‘-’, no
s an increase in resistance. A cut-off of p < 0.01 was used for statistical signiﬁcance
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the lowest levels of resistance to minocycline (7%). Tigecycline was
active against A. baumannii isolates at a MIC90 of 2 mg/L (Table 5).
The global rate of MDR A. baumannii increased signiﬁcantly
between 2004 and 2014 (p < 0.0001) (Table 1). Global rates of
resistance to amikacin, cefepime, ceftazidime, ceftriaxone, levo-
ﬂoxacin, meropenem, minocycline, and piperacillin–tazobactam
also increased signiﬁcantly between 2004 and 2014 (p < 0.0001)
(Table 5).
3.2.4. Pseudomonas aeruginosa
Of the 2535 P. aeruginosa isolates submitted globally between
2010 and 2014, 9% were MDR (Table 1). Rates of multidrug
resistance were lowest in North America and Europe (4% and 9%,
respectively), and highest in Latin America (31%) (Table 2).
Between 2010 and 2014 there was a signiﬁcant decrease in
MDR P. aeruginosa (p < 0.0001) (Table 1).
Among P. aeruginosa isolates collected between 2010 and
2014 the highest levels of global resistance were observed against
levoﬂoxacin (25%), although resistance signiﬁcantly decreased
from 31% in 2010 to 21% in 2014 (p < 0.01) (Table 5). Resistance to
meropenem was 18%. Signiﬁcant decreases in resistance were
observed for cefepime (14% in 2010 to 6% in 2014; p < 0.01),
ceftazidime (24% in 2010 to 8% in 2014; p < 0.0001), and
piperacillin–tazobactam (21% in 2010 to 6% in 2014;
p < 0.0001). Resistance to amikacin was low among isolates of
P. aeruginosa (4%). Tigecycline was active at a MIC90 of 16 mg/L
(Table 5).
Pooled data for the 2004 to 2014 period show no signiﬁcant
change in global rates of MDR P. aeruginosa. Among isolates of P.
aeruginosa there was a signiﬁcant decrease in resistance to
levoﬂoxacin between 2004 and 2014 (p < 0.01) (Table 5).
4. Discussion
This report shows that although global rates of antimicrobial
resistance among Gram-positive and Gram-negative organisms
isolated from integumentary sources remain high, the rates of
resistance among resistance phenotypes including MRSA and
ESBL-producing Enterobacteriaceae appear to be stabilizing.
This report identiﬁes signiﬁcant increases in rates of MDR
A. baumannii. Signiﬁcant increases in rates of resistance among
A. baumannii to a wide range of antimicrobials including
carbapenems, cephalosporins, ﬂuoroquinolones, and b-lacta-
mase inhibitors between 2010 and 2014 (and 2004–2014) were
also seen.
As shown by the results in this report, global rates of MRSA
remained stable among isolates from integumentary sources
(ranging from 34% to 40% between 2010 and 2014), and were
unchanged from the overall global rate reported by Namdari et al.
(41%).12 Regionally, rates in Europe, Latin America, and North
America were also consistent over the time period, with the
highest overall rates of MRSA reported for Latin America (55%) and
North America (50%). Rates in Africa and the Middle East were
more variable, and this is likely due, in part, to the low numbers of
isolates collected in some years. This stabilization of MRSA rates is
consistent with previous reports from European countries,17–19 as
well as North America;20 however supporting data for Latin
America are lacking. More information is also needed for the Africa
and Middle East regions.
Linezolid, tigecycline, and vancomycin are effective in treating
cSSSIs due to S. aureus, including MRSA.21,22 All isolates of S. aureus
collected in this study were susceptible to these agents, however
the activity of these antimicrobials should continue to be
monitored. Over recent years there have been reported outbreaks
of linezolid-resistant MRSA,23,24 although data from globalsurveillance studies have shown low levels of linezolid resistance
(<1% of S. aureus isolates).25–27
Linezolid-resistant enterococci have also been reported by
surveillance studies,26,28 and our report showed the sporadic
occurrence of linezolid-resistant enterococci, with one linezolid-
resistant E. faecium isolate reported from Europe in 2010. Namdari
et al. also reported low numbers of linezolid-resistant enterococci
(four isolates).12
As described above, all isolates of S. aureus were susceptible to
tigecycline. Among the enterococci, all isolates of E. faecium and
99.8% of E. faecalis were susceptible to tigecycline at a breakpoint of
0.25 mg/L. Among Enterobacteriaceae, 99.9% of E. coli and 94% of
K. pneumoniae were susceptible to tigecycline at a breakpoint of
2 mg/L. Similar activity was reported by Namdari et al. between
2004 and 2009, suggesting that the in vitro activity of tigecycline
against integumentary isolates is unchanged.12 Other agents that
maintained their activity against Gram-positive organisms in this
study included meropenem, linezolid, and vancomycin. Regarding
the Enterobacteriaceae, meropenem and amikacin showed high
antimicrobial activity, which is also supported by the data
presented by Namdari et al.12 Among the non-Enterobacteriaceae,
the MIC90 for tigecycline against isolates of A. baumannii and
P. aeruginosa were 2 mg/L and 16 mg/L, respectively. Tigecycline is
not active clinically against P. aeruginosa.29 The MIC90 against
A. baumannii was similar to that reported by Namdari et al.12
The global rates of ESBL production among E. coli and
K. pneumoniae between 2010 and 2014 reported herein (16%
and 22%, respectively) are comparable with those in the earlier
report by Namdari et al. (12% and 20%, respectively).12 Global
surveillance reports from the Study for Monitoring Antimicrobial
Resistance Trends (SMART) have reported the rates of ESBL-
producing E. coli (9% in 2002 to 21% in 2010)30 and ESBL-producing
K. pneumoniae (2008–2009, 22%) isolated from intra-abdominal
infections.31 In this T.E.S.T. report, higher percentages of ESBL-
producing E. coli and ESBL-producing K. pneumoniae were isolated
from Latin America (33% and 41%, respectively) and the lowest
from North America (7% and 9%, respectively). These results are
comparable with those of Namdari et al.12 and Hawser et al.30,31
Between 2004 and 2014, signiﬁcant increases in resistance
among K. pneumoniae to amoxicillin–clavulanate, cefepime,
ceftriaxone, levoﬂoxacin, meropenem, piperacillin–tazobactam,
and tigecycline were seen. Similarly there were signiﬁcant
increases in resistance among E. coli to ampicillin, cefepime,
ceftriaxone, and levoﬂoxacin. Namdari et al. reported increasing
levels of resistance among K. pneumoniae and E. coli between
2004 and 2009.12 Our report shows a further increase in resistance
in 2010; however this was followed by a stabilization in resistance
rates (<10% change in resistance) between 2011 and 2014. Despite
signiﬁcant increases in carbapenem resistance among K. pneumo-
niae and E. coli, these antimicrobial agents remain the most active.
Hawser et al. reported similar results, showing that susceptibility
among K. pneumoniae and E. coli to the majority of antimicrobial
agents either ﬂuctuated slightly or decreased; however this
decrease in susceptibility was less for carbapenems.30,31 They
also reported that susceptibility to amikacin, cephalosporins,
ﬂuoroquinolones, and b-lactamase inhibitors decreased over
time.30,31
Worldwide, A. baumannii and P. aeruginosa, including MDR
strains, are serious nosocomial pathogens and are intrinsically
resistant to many antimicrobials.32,33 Our study showed high rates
of MDR A. baumannii (43%), with signiﬁcant increases in MDR
strains between 2010–2014 and 2004–2014. In contrast, less than
10% of P. aeruginosa isolates were MDR strains. By region, the
highest rates of multidrug resistance among MDR A. baumannii and
MDR P. aeruginosa were in Latin America and the lowest in North
America. This geographical difference in resistance has been
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submitted in this report, resistance to the majority of antimicro-
bials signiﬁcantly increased, including resistance to carbapenems,
which have previously been reported as the most active agents
against non-Enterobacteriaceae.35 This report also highlighted
increasing numbers of MDR A. baumannii.35 These results are
comparable with resistance rates reported by Namdari et al., and
are reﬂected by signiﬁcant increases in resistance among
A. baumannii between 2004 and 2014 to these antimicrobials.12
Surveillance data have shown increasing rates of MDR Acinetobacter
spp. and increasing resistance to meropenem (43.4%) and imipenem
(42.5%).35More recently, Morfı´n-Otero et al. reported on A. baumannii
infections in a tertiary care teaching hospital in Mexico over a 13-year
period and showed that the susceptibility of A. baumannii to
meropenem decreased from 92% in 1999 to 12% in 2011.36 They
reported that A. baumannii was one of the most frequently isolated
pathogens, overtaking P. aeruginosa, and was the second most
common Gram-negative pathogen after E. coli in 2011.36
Among isolates of E. faecalis, E. faecium, K. pneumoniae, and E.
coli, resistance to minocycline decreased signiﬁcantly by 12%–41%
between 2010 and 2014. Namdari et al. previously reported the
opposite; increasing levels of minocycline resistance among these
organisms between 2004 and 2009, and concluded that the reason
for the initial increase in minocycline was unclear.12 Among the
Gram-negative isolates (K. pneumoniae and E. coli), resistance to
minocycline in 2014 was comparable with that reported by
Namdari et al. in 2004.12 Minocycline resistance among Gram-
positive isolates of E. faecalis and E. faecium in 2014 was lower than
that reported by Namdari et al. in 2004 (difference of 5–15%).12 To
the authors’ knowledge, such changes in susceptibility to
minocycline have not been reported by other studies. Following
this increase, the largest decrease in minocycline resistance
was seen between 2010 and 2011 and this may be due to the
decrease in the number of centres submitting isolates between
these two years.
The discussion above highlights one of the limitations of this
study; the varying number of participating centres between years.
A second limitation of the T.E.S.T. study is the regional distribution
of centres. Europe and North America accounted for 82% of
participating centres in this study; therefore the results are heavily
inﬂuenced by these regions. In addition, centres from the Asia-
Paciﬁc region were not involved in T.E.S.T. between 2010 and 2014,
which impacts the global spread of the study. As an example, a
total of 6% of the S. aureus reported by Namdari et al. came from the
Asia-Paciﬁc region.12 Some of the CLSI breakpoints applied in this
study have been updated since the study by Namdari et al.,12
speciﬁcally, cefepime and the Enterobacteriaceae, the carbape-
nems and A. baumannii, and piperacillin–tazobactam, ceftriaxone,
and the carbapenems and P. aeruginosa. Such changes should be
borne in mind when comparing the studies.
In conclusion, resistance among pathogens involved in integu-
mentary infections remains high, with global rates of MRSA at 38%
and MDR A. baumannii at 43%. Despite high rates of MRSA
resistance and resistance among ESBL-producing Enterobacter-
iaceae, these rates appear to be stabilizing. Few agents were active
in vitro against A. baumannii and P. aeruginosa except for
carbapenems, which, unfortunately, show increasing resistance
compared to earlier years, giving cause for concern. Tigecycline
was also active against A. baumannii but not P. aeruginosa. Among
Gram-positive organisms isolated from integumentary sources,
meropenem, linezolid, vancomycin, and tigecycline maintained
their in vitro activity. Meropenem, amikacin, and tigecycline also
continue to be active against Enterobacteriaceae. These trends
highlight the importance of global and regional antimicrobial
surveillance studies to help monitor resistance rates among
clinically important pathogens.Acknowledgements
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